SynthesisJournal of cancer research and clinical oncology2015
Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis.
Synthesis in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.Stem cell research & therapy · 2021Pooled it
- CD56-Positive Acute Myeloid Leukemia Complicated by Hemophagocytic Lymphohistiocytosis: A case report and narrative review.Pakistan journal of medical sciences · 2026Article
- Characterization of Acute Myeloid Leukemia With t(16;21) Translocation: Cytogenetic, Molecular, and Immunophenotypic Findings.World journal of oncology · 2026Article
- Allo-HSCT Might Improve Long-Term Survival in Patients with CD56-Positive AML.Journal of blood medicine · 2026Article
- CD56 on immune and tumor cells: what is known and beyond?Clinical and experimental immunology · 2025Review
- Article
- HEMOPHAGOCYTOSIS BY BLASTS IN A CHILD WITH ACUTE MONOCYTIC LEUKEMIA AFTER CHEMOTHERAPY.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2021Article
- High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.Journal of translational medicine · 2019Article
- Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Frontiers in oncology · 2018Review
- Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- [The analysis of prognosis-associated factors in adults with acute promyelocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- Exploring functions of long noncoding RNAs across multiple cancers through co-expression network.Scientific reports · 2017Article
- CD56 in the Immune System: More Than a Marker for Cytotoxicity?Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeExtensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue.
methodsA systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated.
resultsTotally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30-3.78) and DFS (HR 2.63; 95 % CI 1.10-6.29) and increased RR (OR 3.29; 95 % CI 1.67-6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49-1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66-3.57) and DFS (HR 4.27; 95 % CI 1.15-15.78), increased RR (OR 3.11; 95 % CI 2.01-4.81), and decreased CRR (OR 0.42; 95 % CI 0.25-0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38-2.19) and DFS (HR 2.38; 95 % CI 1.87-3.02), increased RR (OR 5.19; 95 % CI 2.84-9.48), and decreased CRR (OR 0.62; 95 % CI 0.41-0.96).
conclusionsThis meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.